The FDA is tightening its rules around vaccine approvals, especially concerning children. This shift follows concerns raised by top officials about the risks of COVID vaccines.
On a recent Fox News segment, FDA Commissioner Marty Makary stated that the agency will no longer “rubber-stamp” products that don’t prove effective. He emphasized the need for rigorous testing, insisting that past practices undermined scientific integrity.
This announcement came after insights from Dr. Vinay Prasad, the FDA’s leading vaccine regulator, revealed plans to change how the agency reviews vaccines. These changes include revealing truths in vaccine labels and requiring manufacturers to demonstrate that new pneumonia vaccines actually reduce disease, not just trigger antibody production.
Prasad also indicated a more cautious approach for vaccines given to pregnant women, now facing stricter scrutiny. He raised concerns about the practice of administering multiple vaccines at once, a standard approach until now.
As a result, these changes could make seeking vaccine approval longer and more costly, potentially affecting the availability of vaccines that have historically been safe and effective in preventing diseases.
### Linking Vaccines to Adverse Events
During his Fox News appearance, Makary claimed that ten children had died from the COVID vaccine during the Biden administration, though he didn’t provide details that clarified this assertion. Millions of children have received the vaccine, leading to questions about the accuracy of these claims.
An internal FDA email suggested an evaluation of 96 deaths reported between 2021 and 2024 was conducted, determining that ten occurred “after and because of” the vaccine. However, some experts, like Dr. Paul Offit from the Children’s Hospital of Philadelphia, argue that the evidence should be shared for public scrutiny rather than relying solely on claims without clear backing.
Dr. Jesse Goodman, a former FDA official, supports the current acceptance of antibody levels as valid during the vaccine approval process, saying it effectively ensures timely access to necessary vaccines.
### Challenging Perspectives on Vaccine Effectiveness
Epidemiologist Michael Osterholm has also weighed in, critiquing Prasad’s comments and suggesting the FDA’s stance on COVID’s severity in children misconstrues facts. He noted that during the pandemic, there were 1,597 deaths attributed to COVID in children from 2020 to 2022. Osterholm argues that the new claims should undergo thorough review by independent experts before being widely accepted.
The FDA operates a surveillance system called the Vaccine Adverse Event Reporting System (VAERS), which collects reports of adverse events related to vaccinations. However, the FDA clarifies that these reports do not establish a cause-and-effect relationship.
Makary mentioned that the perception of the COVID vaccine’s necessity has shifted dramatically since its initial rollout, particularly emphasizing its effectiveness for high-risk groups.
### Upcoming Meetings That Could Change Vaccine Policies
The FDA’s changes come at a crucial time, with the CDC’s Advisory Committee on Immunization Practices set for a significant meeting to review childhood vaccination schedules. Experts worry that potential alterations, such as delaying vaccines or changing their composition, could result in fewer immunized children and a resurgence of diseases once thought to be under control.
Moderna, which has a COVID vaccine approved for children as young as six months, asserts that extensive studies confirm the safety of its vaccine. They indicated that no new safety concerns have been reported after distributing over one billion doses worldwide.
Pfizer has not yet commented on these changes or claims surrounding its vaccine.
The evolving landscape of vaccine approval and oversight continues to prompt debate among health experts, the FDA, and the public. As decisions unfold, how they shape future vaccination protocols remains to be seen.
Source link
